New patients treated for PNE with desmopressin should only be prescribed an oral formulation. PNE新患者仅限用去氨加压素的口服剂型。
Objective To study the adverse drug reaction ( ADR) of desmopressin ( DDAVP) in clinical application, improving clinical medication. 目的了解和分析去氨加压素在临床应用中不良反应,促进临床合理用药。
All intranasal formulations of desmopressin are now contraindicated for the treatment of PNE. 从现在开始去氨加压素所有鼻腔用剂型都禁忌用于PNE。
Prebiopsy desmopressin administration decreases the risk of bleeding and hematoma size in patients undergoing percutaneous kidney biopsy without a cost increase. 在经皮肾穿刺患者中,穿刺前给予去氨加压素减少出血风险、减少血肿大小,而不增加住院费用。
All patients using intranasal formulations of desmopressin for treatment of PNE should be reassessed to determine their need for continued treatment and to discuss other options. 要对所有正在使用鼻腔用去氨加压素的患者进行重新评估,来决定是继续用药还是选择别的治疗方案。
Treatment of Primary Enuresis With Desmopressin Acetate 醋酸去氨加压素治疗原发性遗尿症
Desmopressin in functional endoscopic sinus surgery 去氨加压素用于鼻窦内镜手术的临床研究
Effect of Desmopressin on the Activated Clotting Time of the Patients Undergoing Extracorporeal Circulation 去氨加压素对体外循环病人术后激活凝血时间的影响